Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization

被引:837
作者
Li, MY
Chen, DL
Shiloh, A
Luo, JY
Nikolaev, AY
Qin, J
Gu, W
机构
[1] Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA
[3] Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA
[4] Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nature737
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The p53 tumour suppressor is a short-lived protein that is maintained at low levels in normal cells by Mdm2-mediated ubiquitination and subsequent proteolysis(1-3). Stabilization of p53 is crucial for its tumour suppressor function(1-5). However, the precise mechanism by which ubiquitinated p53 levels are regulated in vivo is not completely understood. By mass spectrometry of affinity-purified p53-associated factors, we have identified herpesvirus-associated ubiquitin-specific protease(6) (HAUSP) as a novel p53-interacting protein. HAUSP strongly stabilizes p53 even in the presence of excess Mdm2, and also induces p53-dependent cell growth repression and apoptosis. Significantly, HAUSP has an intrinsic enzymatic activity that specifically deubiquitinates p53 both in vitro and in vivo. In contrast, expression of a catalytically inactive point mutant of HAUSP in cells increases the levels of p53 ubiquitination and destabilizes p53. These findings reveal an important mechanism by which p53 can be stabilized by direct deubiquitination and also imply that HAUSP might function as a tumour suppressor in vivo through the stabilization of p53.
引用
收藏
页码:648 / 653
页数:7
相关论文
共 50 条
[31]   HAUSP, a deubiquitinating enzyme for p53, is polyubiquitinated, polyneddylated, and dimerized [J].
Lee, HJ ;
Kim, MS ;
Kim, YK ;
Oh, YK ;
Baek, KH .
FEBS LETTERS, 2005, 579 (21) :4867-4872
[32]   The complexity of p53 stabilization and activation [J].
Lavin, M. F. ;
Gueven, N. .
CELL DEATH AND DIFFERENTIATION, 2006, 13 (06) :941-950
[33]   Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment [J].
Hrstka, Roman ;
Coates, Philip J. ;
Vojtesek, Borivoj .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2009, 13 (03) :440-453
[34]   Contribution of the p53 pathway in cancers that carry wild-type p53 [J].
Ohki, Rieko .
CANCER SCIENCE, 2022, 113 :1232-1232
[35]   p53 β-hydroxybutyrylation attenuates p53 activity [J].
Liu, Kun ;
Li, Fangzhou ;
Sun, Qianqian ;
Lin, Ning ;
Han, Haichao ;
You, Kaiqiang ;
Tian, Feng ;
Mao, Zebin ;
Li, Tingting ;
Tong, Tanjun ;
Geng, Meiyu ;
Zhao, Yingming ;
Gu, Wei ;
Zhao, Wenhui .
CELL DEATH & DISEASE, 2019, 10 (3)
[36]   p53 β-hydroxybutyrylation attenuates p53 activity [J].
Kun Liu ;
Fangzhou Li ;
Qianqian Sun ;
Ning Lin ;
Haichao Han ;
Kaiqiang You ;
Feng Tian ;
Zebin Mao ;
Tingting Li ;
Tanjun Tong ;
Meiyu Geng ;
Yingming Zhao ;
Wei Gu ;
Wenhui Zhao .
Cell Death & Disease, 10
[37]   p53 isoforms change p53 paradigm [J].
Bourdon, J. C. .
MOLECULAR & CELLULAR ONCOLOGY, 2014, 1 (04)
[38]   The Δ133p53 Isoforms, Tuners of the p53 Pathway [J].
Joruiz, Sebastien M. ;
Beck, Jessica A. ;
Horikawa, Izumi ;
Harris, Curtis C. .
CANCERS, 2020, 12 (11) :1-20
[39]   Polymorphic variants in the p53 pathway [J].
Murphy, M. E. .
CELL DEATH AND DIFFERENTIATION, 2006, 13 (06) :916-920
[40]   The pathology according to p53 pathway [J].
Hatano, Yuichiro .
PATHOBIOLOGY, 2024, 91 (03) :230-243